Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 43,946	$ 22,895
Restricted cash	4,409
Accounts receivable, net	2,789	302
Receivable from Sanofi		30,557
Inventory	2,657	2,331
Asset held for sale		16,730
Deferred costs from commercial product sales	405	309
Prepaid expenses and other current assets	3,010	4,364
Total current assets	57,216	77,488
Property and equipment, net	26,922	28,927
Other assets	437	648
Total assets	84,575	107,063
Current liabilities:
Accounts payable	6,984	3,263
Accrued expenses and other current liabilities	12,449	7,937
Facility financing obligation	52,745	71,339
Deferred revenue, net	3,038	3,419
Deferred payments from collaboration - current	250	1,000
Recognized loss on purchase commitments - current	12,131	5,093
Total current liabilities	87,597	92,051
Note payable to principal stockholder	79,666	49,521
Accrued interest - note payable to principal stockholder	2,347	9,281
Senior convertible notes	24,411	27,635
Recognized loss on purchase commitments - long term	97,585	95,942
Warrant liability		7,381
Deferred payments from collaboration - long term	500
Milestone rights liability and other liabilities	7,201	8,845
Total liabilities	299,307	290,656
Commitments and contingencies (Note 14)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2017 and 2016
Common stock, $0.01 par value - 280,000,000 and 140,000,000 shares authorized, 119,053,414 and 95,680,831 shares issued and outstanding at December 31, 2017 and 2016, respectively	1,192	957
Additional paid-in capital	2,638,992	2,553,039
Accumulated other comprehensive loss	(18)	(24)
Accumulated deficit	(2,854,898)	(2,737,565)
Total stockholders' deficit	(214,732)	(183,593)
Total liabilities and stockholders' deficit	$ 84,575	$ 107,063